Antibiotice (LTS:0DMW) Institutional Ownership: 0.10% (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0DMW Antibiotice SA LTS:0DMW
79 GF Score
Price lei0.51
GF Value lei0.53
! 7 Warning Signs
View Full Analysis

What is Antibiotice Institutional Ownership?

Antibiotice LTS:0DMW 79 Institutional Ownership is 0.10% as of Aug. 27, 2026. GuruFocus rates LTS:0DMW with a GF Score™ of 79/100 and a GF Value™ of lei0.53. The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Antibiotice's institutional ownership is 0.10%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Antibiotice's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Antibiotice's Float Percentage Of Total Shares Outstanding is 0.00%.

Antibiotice Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Antibiotice's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antibiotice Institutional Ownership Chart

Antibiotice Historical Data

The historical data trend for Antibiotice can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31
Institutional Ownership 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10
LTS:0DMW
79GF Score
Antibiotice SA LTS:0DMW
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antibiotice Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.10% mean?
Antibiotice (LTS:0DMW) has a Institutional Ownership of 0.10% as of Aug. 27, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Antibiotice and its competitors.
Is Antibiotice's Institutional Ownership too high?
Antibiotice's current Institutional Ownership is 0.10%. Overall, Antibiotice has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Antibiotice's Institutional Ownership compare to ZTS and UTHR?
Antibiotice's Institutional Ownership of 0.10% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Antibiotice and its competitors. Antibiotice's current Institutional Ownership is 0.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antibiotice stock overvalued right now?
Antibiotice (LTS:0DMW) has a current Institutional Ownership of 0.10%. The stock's GF Value™ is lei0.53, compared to a current price of lei0.51 — trading 4.6% below its estimated fair value. The current Institutional Ownership is 0.10%. Antibiotice's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Antibiotice (LTS:0DMW), the current Institutional Ownership is 0.10% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Antibiotice (LTS:0DMW) Overvalued in 2026?

Based on GuruFocus' analysis, Antibiotice stock appears to be undervalued. The current stock price of lei0.51 is trading 4.6% below its estimated GF Value™ of lei0.53.

Key valuation signals for LTS:0DMW:

  • Institutional Ownership: 0.10%
  • GF Value™: lei0.53 vs. price of lei0.51 (4.6% below fair value)
  • GF Score™: 79/100 with 7 warning signs

No single metric tells the full story. See the LTS:0DMW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Antibiotice Business Description

Other Exchanges ATB:Romania
Address 1 Valea Lupului Street, Iasi, ROU, 707410
Antibiotice SA is a Romania based company engaged in manufacturing generic medicines. It primarily develops and produces generic medicines for human use, veterinary medicines and active substance Nystatin. The group's generic medicines are primarily targeted at patients with infections, dermatological, cardiovascular, digestive tract diseases or diseases of the musculoskeletal system. It manufactures firm powders for solutions for injection and suspensions for injection (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels, creams).
79GF Score

Get the complete analysis for LTS:0DMW

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei0.51
Price
lei0.53
GF Value